drugset
drugset / Trial / NCT06283550

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

NCT06283550 ↗

Phase 2 Completed 82 enrolled Innovaderm Research Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the safety, efficacy and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.

Timeline

Start
2024-05-31
Primary completion
2025-06-18
Completion
2025-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Abrocitinib Small molecule 100 mg Oral
Subject Abrocitinib Small molecule 200 mg Oral

Indications

No indication recorded.